We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
NuVasive has received conditional approval of an investigational
device exemption (IDE) from the FDA to begin clinical trial enrollment of its NeoDisc cervical disc replacement device.
An experimental device appears to be effective in eliminating or reducing migraine headaches when administered during the onset of the migraine, according to a study conducted at the Ohio State University (OSU) Medical Center.
Smith & Nephew Orthopaedics Trauma & Clinical Therapies and Q-MED AB today announced that they have formed a strategic alliance to develop and commercialize Q-MED's proprietary technology for the production of stabilized non-animal hyaluronic acid, NASHA for orthopedic uses.
NuVasive, Inc., a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today it has received conditional approval of an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin clinical trial enrollment of its NeoDisc cervical disc replacement device.
The Queen Elizabeth II Health Sciences Centre, the Faculty of Medicine at Dalhousie University and the Brain Repair Centre have announced the first successful surgery in Canada to implant the Precision Spinal Cord Stimulation (SCS) system, an advanced medical device that provides relief for patients living with chronic pain.
Cincinnati Children's Hospital Medical Center has signed an exclusive agreement with Abbott Diagnostics to develop a test to detect kidney injury and disease.
Tuesday, Affymetrix Inc. said that it granted Epigenomics AG non-exclusive access to its microarray technology to develop and market microarray-based in-vitro diagnostic or IVD tests for oncology and other indications.